Alyeska Investment Group
CDTX

Alyeska Investment Group’s Cidara Therapeutics CDTX Stock Holding History

Alyeska Investment Group’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,628
Closed -$481K – 418
2018
Q2 		$481K Sell
4,628
-212
-4% -$20K ﹤0.01% 424
2018
Q1 		$387K Sell
4,840
-44
-0.9% -$6.01K ﹤0.01% 418
2017
Q4 		$664K Hold
4,884
– – 0.01% 400
2017
Q3 		$791K Buy
4,884
+88
+2% +$12.5K 0.01% 428
2017
Q2 		$719K Sell
4,796
-146
-3% -$20.2K 0.01% 422
2017
Q1 		$771K Sell
4,942
-58
-1% -$10.2K 0.01% 444
2016
Q4 		$1.04M Buy
+5,000
New +$1.04M 0.01% 422
2015
Q4 		– Sell
-6,072
Closed -$1.54M – 388
2015
Q3 		$1.54M Buy
6,072
+481
+9% +$138K 0.02% 352
2015
Q2 		$1.57M Buy
+5,591
New +$1.72M 0.02% 369

Other funds holding CDTX

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Alyeska Investment Group's CDTX Position: Q3 2018 in Review

Alyeska Investment Group sold out of Cidara Therapeutics (CDTX) in Q3 2018, closing a stake of 4,628 shares — an estimated $481K sold.

Alyeska Investment Group first reported a position in CDTX in Q2 2015 and held it in 9 quarters. The position peaked at $1.57M in Q2 2015. 59 funds tracked by Wall St. Rank hold CDTX as of Q3 2018.

  • Alyeska Investment Group reported no remaining Cidara Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 4,628 Cidara Therapeutics shares in Q3 2018, an estimated $481K.
  • Alyeska Investment Group first reported a position in Cidara Therapeutics in Q2 2015 and held it in 9 quarters.
  • Alyeska Investment Group's Cidara Therapeutics position peaked at $1.57M in Q2 2015.
  • 59 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2018.

Based on Alyeska Investment Group's 13F filing for Q3 2018, filed 14 Nov 2018.